LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS

11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its own technology (Trimerbody®), opens a financing round of € 1M through the investment platform specialized in biomedicine, Capital Cell. The goal is to continue its research for its first third generation immuno-oncological agent against advanced cancers of the lung, breast and colon. Specifically, the forecast is to finance Phase I studies of its bispecific Trimerbody in patients with advanced or resistant cancers without a therapeutic option. Currently, € 4M have already been achieved, 80% of the investment of the planned amount, through three relevant venture capital funds, Inveready acting as leading investor, SODENA and CDTI innvierte.

If the results are as expected, the company will be able to develop additional products against any type of cancer. A problem that, in many cases, does not have efficacious treatments and that affects many millions of people around the world.

"Trimerbody has proven to be an especially safe product and preclinical studies led us to expect good results in the clinical trial," stated Dr. Marta Compte MD, PhD, Director of Research and Development at LEADARTIS.

"We hope that our work contributes to improving the lives of many people, especially cancer patients without a therapeutic alternative," says Dr. Juan J. Pérez Villar, CEO of LEADARTIS with extensive experience in the United States in the development of anti-cancer drugs. Other international companies developing cancer treatments, without the potential of our technology, already have capitalization values ​​of up to € 1000M.

LEADARTIS started its project in 2014 and has the support of important investment groups such as venture capital entities including Inveready (http://inveready.com/ ) and Sodena (Sociedad de Desarrollo de Navarra, www.sodena.com ).

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000
14-05-2021

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis
30-04-2021

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021